摘要
目的探讨新辅助化疗治疗卵巢癌的疗效及对免疫功能的影响。方法采用随机数字表法将76例卵巢癌患者分为对照组与观察组,每组38例。对照组患者予以肿瘤细胞减灭术+术后腹腔热灌注+术后化疗方案,观察组在对照组的基础上给予术前新辅助化疗。比较两组患者的治疗一般情况、疗效及不良反应;比较不同时间两组患者的免疫指标;对患者随访1年,观察其复发及生存情况。结果观察组患者手术时间、住院时间均短于对照组,腹腔积液量、术中出血量均少于对照组,术后感染发生率低于对照组,差异均有统计学意义(P﹤0.05)。腹腔热灌注后、化疗后,观察组患者CD3^(+)CD4^(+)、CD3^(+)CD56^(+)、CD3^(+)CD4^(+)/CD3^(+)CD8^(+)均高于本组化疗前、手术后及对照组,差异均有统计学意义(P﹤0.05)。观察组患者临床疗效优于对照组,差异有统计学意义(P﹤0.05)。两组患者复发情况及生存情况比较,差异均无统计学意义(P﹥0.05)。观察组患者不良反应总发生率低于对照组,差异有统计学意义(P﹤0.05)。结论术前应用新辅助化疗可以帮助缩短细胞减灭术的手术时间,减少患者腹腔积液量,一定程度上有利于实施后续化疗方案,能够达到满意的细胞减灭术目的。此外,还能进一步激活机体的免疫系统,改善患者的免疫抑制,提高最终的治疗效果,临床安全性相对较好。
Objective To investigate the efficacy of neoadjuvant chemotherapy in the treatment of ovarian cancer and its impact on immune function.Method A total of 76 ovarian cancer patients were divided into control group and observation group by random number table method,with 38 cases in each group.Patients in the control group received tumor cytoreductive surgery plus intraperitoneal hyperthermic perfusion plus postoperative chemotherapy.The observation group was given preoperative neoadjuvant chemotherapy based on the control group.The body condition,curative effect,and adverse events of the two groups were compared.The immune indexes of two groups were compared at different times.The patients were followed up for 1 year to observe their recurrence and survival.Result The operation time and hospitalization time of the observation group were significantly shorter,the peritoneal effusion and intraoperative blood loss were significantly less,and the incidence of postoperative infection was significantly lower than those of the control group,and the differences were statistically significant(P<0.05).After intraperitoneal hyperthermic perfusion and chemotherapy,CD3^(+)CD4^(+),CD3^(+)CD56^(+),and CD3^(+)CD4^(+)/CD3^(+)CD8^(+)in the observation group were higher than those before chemotherapy,after surgery in the same group and those in the control group,and the differences were statistically significant(P<0.05).The clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).There were no significant differences in recurrence and survival between the two groups(P>0.05).The total incidence of adverse events in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Preoperative application of neoadjuvant chemotherapy could help shorten the operation time of cytoreductive surgery,reduce the amount of peritoneal effusion in patients,facilitate the implementation of subsequen
作者
贾惠惠
程艳丽
黄喜英
宋迎春
JIA Huihui;CHENG Yanli;HUANG Xiying;SONG Yingchun(Department of Gynaecology and Obstetrics,Xi’an No.1 Hospital,Xi’an 710000,Shaanxi,China;Department of Gynaecology and Obstetrics,Xi’an Gaoxin Hospital,Xi’an 710000,Shaanxi,China)
出处
《癌症进展》
2022年第23期2437-2440,共4页
Oncology Progress
关键词
新辅助化疗
卵巢癌
免疫功能
疗效
neoadjuvant chemotherapy
ovarian cancer
immune function
curative effect
